within Pharmacolibrary.Drugs.ATC.L;

model L01XK52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.2833333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 1.07,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>This is a fixed-dose combination medication containing niraparib, a PARP inhibitor used primarily in ovarian cancer, and abiraterone acetate, a selective CYP17 inhibitor used in the treatment of metastatic castration-resistant prostate cancer. The combination is intended for treatment of adult patients with certain types of prostate cancer and was approved by the European Union in May 2023.</p><h4>Pharmacokinetics</h4><p>No published literature with population or compartmental pharmacokinetic models for the fixed-dose combination of niraparib and abiraterone (L01XK52) is currently available as of June 2024. Parameter estimates were inferred based on the pharmacokinetic characteristics of individual components and regulatory approval documentation.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XK52;
